News and Press Releases
FDA Grants OKYO Pharma Fast Track Designation to Urcosimod for Neuropathic Corneal Pain
1 May 2025 -- London, UK and New York, US -- OKYO Pharma Limited, an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod (formerly called OK-101) to treat NCP, an ocular...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: May 1, 2025
Pharming receives positive recommendation from NICE for Joenja▼(leniolisib) as a treatment for APDS
Joenja® is the first and only medicine specifically for APDS to be reimbursed within the NHS Recommended for adult and pediatric patients 12 years of age and older with activated...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 23, 2025
Pharming Group N.V. Vondellaan 47 2332 AA Leiden The Netherlands
Innovent Dosed First Participant in Phase 3 Clinical Study of IBI354 (Novel HER2 ADC) for Platinum-resistant Ovarian Cancer
24 March 2025 -- California, US and Suzhou, China -- Innovent Biologics, Inc, a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology,...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 24, 2025
PulseSight Therapeutics announces the initiation of the clinical plan of PST-611, Transferrin Vectorized Therapy for dry AMD/Geographic Atrophy
14 January 2025 -- Paris, France -- PulseSight Therapeutics SAS, an ophthalmology biotech company developing disruptive non-viral vectorized therapies with minimally-invasive delivery technology, today announces it has submitted a Clinical...
Category: Biotechnology, Clinical Trials, Drug Discovery, Pharmaceutical
Posted: January 14, 2025
PariSanté Campus, 2-10 Rue d’Oradour-sur-Glane, 75015 Paris
From Discovery Park to Merck, Top Industry Players to Showcase at London Biotechnology Show 2025
7 November 2024 -- London, UK -- Back for its second year, the London Biotechnology Show (#LBS25) gathers prominent biotech leaders, policymakers, and industry enthusiasts for an unparalleled showcase. Attendees...
Category: Biotechnology, Other, Pharmaceutical
Posted: November 7, 2024
Rentschler Biopharma announces largest single investment at its headquarters in Germany
Construction of a new buffer media facility in Laupheim Largest investment in the German site; project duration of approx. three years Continuous modernization, automation, and digitalization of the site. 24...
Category: Biotechnology, Manufacturing and Packing, Other
Posted: October 24, 2024
CPHI Milan analysis ‘Lombardy the best location for pharma manufacturing in Europe’
Report predicts significant growth for Lombardy’s pharma industry in 2025 as event directly contributes more than €120m to region 3 October 2024 – Milan, Italy – The global pharma industry...
Category: Pharmaceutical
Posted: October 3, 2024
PlaqueTec and RxCelerate collaborate on early phase drug discovery for coronary artery disease
Project evaluated small molecules against novel target in coronary artery disease discovered by PlaqueTec Bespoke cell-based assay developed by RxCelerate to test small molecules predicted to bind candidate target. 18...
Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: September 18, 2024
CPHI Annual Report 2024: CPHI Milan Report predicts BLA and Tides approvals will surpass small molecules within the next three years
Bio and Tides predicted to be the fastest growing modality for CDMOs over the next five years 12 September 2024 – Milan, Italy – Ahead of CPHI Milan – the...
Category: Pharmaceutical
Posted: September 12, 2024
Mission Therapeutics awarded $5.2m from The Michael J Fox Foundation and Parkinson’s UK to advance potential disease-modifying treatment MTX325
Investment will support investigation of Mission’s small molecule drug MTX325 in patients with early-stage Parkinson’s disease Marks latest step in Mission’s relationship with The Michael J Fox Foundation (MJFF), after...
Category: Biotechnology, Clinical Trials, Drug Discovery, Pharmaceutical
Posted: July 2, 2024
Moneta (Building 280), Babraham Research Campus, Cambridge, CB22 3AT, United Kingdom
Exonate appoints Dr Rafiq Hasan as Non-Executive Director
Appointment brings extensive experience in global pharma leadership and progressing ophthalmology drugs to market and further strengthens Board 28 May 2024 -- Cambridgeshire, UK -- Exonate, a biotechnology company developing...
Category: Biotechnology, Pharmaceutical
Posted: May 28, 2024
HepaRegeniX publishes data for its first-in-class MKK4 inhibitor HRX-215 for the treatment of acute and chronic liver diseases in Cell
Clinical and pre-clinical data generated from collaborations between the Tuebingen University Hospital, Germany, researchers from the Mayo Clinic in Rochester, USA and HepaRegeniX HRX-215 proved to be safe and well...
Category: Biotechnology
Posted: March 15, 2024
Exploristics and Exonate announce successful collaboration to enhance clinical trial study design using cloud-based simulation
Exploristics’ cloud-based simulation platform KerusCloud used to enhance study design for Exonate’s upcoming phase 2b study following successful phase 1b/2a study 12 March 2024 -- Cambridgeshire and Belfast, UK --...
Category: Clinical Trials
Posted: March 12, 2024
Exonate first-in-class eye drop phase 1b/2a trial data demonstrate safety and biological activity in treatment of diabetic retinopathy and diabetic macular oedema
EXN407 is the first topical SRPK1 inhibitor to demonstrate both safety and signals of biological response as monotherapy for these indications Data generated fully supports continued clinical development of EXN407...
Category: Clinical Trials
Posted: March 5, 2024
Galimedix Therapeutics announces new pre-clinical data with GAL-201 in an Alzheimer’s disease transgenic model to be presented at AD/PD 2024 Conference
Galimedix’s novel, orally administered small molecule offers the hope of changing the course of disease by targeting amyloid beta oligomers and protofibrils 28 February 2024 -- Maryland, US -- Galimedix...
Category: Biotechnology
Posted: February 28, 2024
